Business · 09/06/2023
FDA Renews Dermatologic and Ophthalmic Drugs Advisory Committee for 2 Years
The FDA has renewed the Dermatologic and Ophthalmic Drugs Advisory Committee for an additional 2 years, with the new charter set to expire on October 7, 2024, following a determination by the Commissioner of Food and Drugs.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →